CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers

Q. Zhou; Z.-r. Ruan; H. Yuan; S. Zeng

doi:10.1055/s-0032-1323696

Arzneimittelforschung, Table of Contents

Arzneimittelforschung 2012; 62(11): 519-524
DOI: 10.1055/s-0032-1323696

Original Article

CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers

Q. Zhou

¹Department of Pharmacy, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang Province, China

,

Z.-r. Ruan

²Division of Clinical Pharmacology, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang Province, China

,

H. Yuan

²Division of Clinical Pharmacology, the 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, Zhejiang Province, China

,

S. Zeng

³Department of Pharmaceutical Analysis & Drug Metabolism, College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, Zhejiang Province, China

› Author Affiliations

Abstract

Objective:

To evaluate the impact of single-nucleotide polymorphisms (SNPs) in CYP2C9, MDR1, SLCO1B1 and ABCG2 on the pharmacokinetics of fluvastatin in Chinese participants.

Methods:

A pharmacokinetic study of fluvastatin (single dose 40 mg) was conducted in 12 healthy Chinese volunteers. Plasma concentrations of fluvastatin were determined by a high-performance liquid chromatography with fluorescence detection. Pharmacokinetic parameters were calculated by non-compartmental method. The SNPs were determined by TaqMan^®(MGB) genotyping assay.

Results:

Effect of CYP2C9*3 (c.1075A>C) on area under the plasma concentration-time curve (AUC) of fluvastatin was statistically significant. Heterozygous variant (C/A) carriers had higher AUC values compared to homozygous wild type (A/A) carriers (922.03±148.17 µg · h · L^− 1 vs. 496.00±168.93 µg · h · L^− 1, P=0.003092). The elimination half-life (T _1/2) values of fluvastatin were longer in MDR1 2677non-G carriers than in MDR1 2677G carriers (2.21±0.47 h vs. 1.25±0.62 h, P=0.02319), and also they were longer in MDR1 1236T-2677non-G-3435T carriers than in MDR1 1236C-2677G-3435C carriers (2.31±0.51 h vs. 1.32±0.62 h, P=0.03320). MDR1 C3435T polymorphism had a significant effect on maximal plasma concentrations (C _max) of fluvastatin. Mutation gene T (TT+CT) carriers had higher C _max values compared to homozygous wild type (C/C) carriers (688.54±142.67 µg · L^− 1 vs. . 413.78±177.83 µg · L^− 1, P=0.01448). Some SNPs such as MDR1 C1236T, ABCG2 c.34G>A, ABCG2 c.421C>A, SLCO1B1 c.388 A>G, SLCO1B1 c.521 T>C, SLCO1B1 c.571 T>C and SLCO1B1 c.597 C>T have no significant effects on fluvastatin pharmacokinetics.

Conclusion:

CYP2C9*3(1075A>C), MDR1 C3435T and MDR1 G2677T/A were determinants of inter-subject variability in fluvastatin pharmacokinetics in healthy Chinese volunteers.

Key words

fluvastatin - pharmacokinetics - single-nucleotide polymorphism - cytochrome p450 - drug transporter

Full Text

References

References
1 Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006; 112: 71-105
2 Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin Pharmacol Ther 2003; 74: 186-194
3 Li J, Volpe DA, Wang Y et al. Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos 2011; 39: 1196-1202
4 Couvert P, Giral P, Dejager S et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008; 9: 1217-1227
5 Bercovich D, Friedlander Y, Korem S et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 2006; 185: 97-107
6 Keskitalo JE, Pasanen MK, Neuvonen PJ et al. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 2009; 10: 1617-1624
7 TaqMan® SNP Genotyping Assays-Applied Biosystems. www3.appliedbiosystems.com
8 Xie HG, Prasad HC, Kim RB et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-1270
9 Luo CH, Wang A, Zhu RH et al. Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese. Br J Clin Pharmacol 2005; 60: 629-631
10 Keskitalo JE, Kurkinen KJ, Neuvonen M et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009; 68: 207-213
11 Balram C, Sharma A, Sivathasan C et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56: 78-83
12 Kalliokoski A, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 2010; 107: 775-781
13 He YJ, Zhang W, Chen Y et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009; 405: 49-52
14 Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006; 80: 356-366
15 Zhang W, Yu BN, He YJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006; 373: 99-103